Trafalgar Scientific Ltd

Medical

Biocytogen | January 15, 2024

Biocytogen Pharmaceuticals Co., Ltd. a global biotech company focusing on the discovery of novel antibody therapeutics, announces that it has entered into an Exclusive Option and License Agreement with Radiance Biopharma Inc. a biotechnology company specializing in developing next generation Antibody Drug Conjugates. The agreement grants Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate (BsADC) for thera...

Siemens | June 11, 2020

Siemens, a process automation specialist, and Exyte, a biopharmaceutical manufacturing facility provider, have joined forces to offer end-to-end solutions for the biopharmaceutical industry.Against the background of the current challenges associated with the Covid-19 pandemic, pharmaceutical companies are facing challenges in developing and mass-producing new vaccines and medicines in existing production facilities. Siemens and Exyte are committed to tackle those challenges. Together, they...

Medical

HealthMyne | September 22, 2021

HealthMyne, a pioneer in applied radiomics, announced that peer-reviewed research recently published in the journal Cancers has demonstrated the ability of its radiomics technology to identify biomarkers that predict whether patients with lung adenocarcinoma would benefit from immunotherapy. In the Cancers article, researchers led by Vincenza Granata evaluated HealthMyne's technology as a quantitative imaging decision support tool for radiomic analysis of lung adenocarcinoma i...

MedTech

Entos Pharmaceuticals, Inc., BioMarin | November 16, 2021

Entos Pharmaceuticals, Inc. (Entos), a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, and BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that they have entered into an agreement that will see Entos apply its Fusogenix nucleic acid delivery technology to promising gene therapy candidates in the BioMarin pipeline. Under the agreement, Entos will create specially formulated product candidate...